Loading...
•
Mar 31, 2022
Allovir Q1 2022 Earnings Report
AlloVir reported financial results for the first quarter ended March 31, 2022.
Key Takeaways
AlloVir reported a net loss of $43.9 million, or $0.69 per share, for the first quarter ended March 31, 2022. The company's research and development expenses were $29.1 million, and general and administrative expenses were $14.1 million. As of March 31, 2022, AlloVir had cash, cash equivalents, and marketable securities of $201.4 million.
Initiated posoleucel registrational study to prevent six devastating viral infections.
FDA granted RMAT designation to posoleucel for Phase 3 multi-virus prevention indication.
Progressed enrollment in three Phase 3 studies for posoleucel and a Phase 2 trial for ALVR106.
Completed enrollment in Phase 2 study of posoleucel for the treatment of BK viremia in kidney transplant patients.
Forward Guidance
AlloVir continues to expect operating expenses to be in the range of $130 million to $145 million for fiscal year 2022, excluding non-cash stock compensation expenses.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...